Drug Profile

APX NEW1

Alternative Names: APX-New; APX-NEW1

Latest Information Update: 28 Jun 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Jun 2022 Preclinical trials in Parkinson's disease in South Korea (unspecified route) (AptaBio Therapeutics pipeline, June 2022)
28 Jun 2022 Pharmacodynamics data from preclinical studies in Parkinson's disease released by AptaBio Therapeutics (AptaBio Therapeutics pipeline, June 2022)
01 Jul 2020 Early research in Brain disorders in South Korea (unspecified route) (Aptabio Therapeutics pipeline, July 2020)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com